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chromosome 9p21 in patients with
sporadic renal cell carcinoma following
surgical resection
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Abstract
Background: Long-term prognostic significance of loss of heterozygosity on chromosome 9p21 for localized renal
cell carcinoma following surgery remains unreported. The study assessed the frequency of deletions of different loci
of chromosome 9p along with immunohistochemical profile of proteins in surgically resected renal cancer tissue
and correlated this with long-term outcomes.
Methods: DNA was extracted from renal tumours and corresponding normal kidney tissues in prospectively collected
samples of 108 patients who underwent surgical resection for clinically localized disease between January 2001 and
December 2005, providing a minimum of 9 years follow-up for each participant. After checking quality of DNA,
amplified by PCR, loss of heterozygosity (LOH) on chromosome 9p was assessed using 6 microsatellite markers in 77
clear cell carcinoma. Only 5 of the markers showed LOH (D9S1814, D9S916, D9S974, D9S942, and D9S171). Protein
expression of p15(INK4b), p16(INK4a), p14(ARF), CAIX, and adipose related protein (ADFP) were demonstrated by
immunostaining in normal and cancer tissues. Loss of heterozygosity for microsatellite analysis was correlated
with tumour characteristics, recurrence free, cancer specific, and overall survival, including significance of
immunohistochemical profile of protein expressions.
Results: The main deletion was found at loci telomeric to CDKN2A region at D9S916. There was a significant correlation
between frequency of LOH stage (p = 0.005) and metastases (p = 0.006) suggesting a higher LOH for advanced and
aggressive renal cell carcinoma. Most commonly observed LOH in the 3 markers: D9S916, D9S974, and D9S942 were
associated with poor survival, and were statistically significant on multivariate analysis. Immunohistochemical expression
of p14, p15, and p16 proteins were either low or absent in cancer tissue compared to normal.
Conclusions: Loss of heterozygosity of p921 chromosome is associated with aggressive tumours, and predicts cancer
specific or recurrence free survival on long-term follow-up.
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Background
Microsatellite alterations in tumor DNA relative to
normal are potential genetic prognostic markers for
RCC. The most common method that is used to detect
these alterations relies on assays which examine two dis-
tinct alleles at a particular location, a condition known
as heterozygosity. A normal tissue specimen is compared
with a tumour sample from the same patient, and DNA
loss is identified if one of the alleles present in the normal
specimen is lost in the tumour, a condition termed as loss
of heterozygosity (LOH). Loss of heterozygosity (LOH) at
chromosome 3p and inactivation of the von Hippel-
Lindau tumor suppressor (VHL) genes are known to have
association with ccRCC [1]. Several studies, including those
of our own group have shown that chromosome 9p has a
critical region of loss in renal cell carcinoma [2–5]. Signifi-
cance of these molecular genetic events on 9p, in particu-
lar, their correlation with the clinical outcomes following
treatment are not fully understood. Investigators previously
used microsatellite markers to identify loss of various loci
on 9p chromosome in renal cell cancer with various fre-
quencies of microdeletions. Grady et al. [6] reported 73,
40, and 23 % loss of heterozygosity at a minimum of 1, 3
and at 4 or more loci respectively in a small series of 60
cases. This study, however, did not report clinical outcomes
or immunohistochemical expression of the cohort, hence,
clinical implications of their findings remain unknown.
Fluorescent in situ hybridization studies have shown
loss of chromosome 9p in renal cancer carries a poor
prognosis [5], but mapping studies on 9p are only a few
and none with long-term outcomes. Frequent allelic loss
has been reported in lung, ovarian, bladder, oral, and
head-and-neck cancers on chromosome 9p21 [2, 7, 8].
The locus on 9p encodes for three cell-cycle inhibitory
proteins: p14ARF, which is encoded by an alternative
reading frame of CDKN2A, p15INK4b, which is encoded
by CDKN2B, and p16INK4a, which is encoded by
CDKN2A. The p14ARF protein activates the key check-
point protein p53, thereby inducing either cell-cycle
arrest (both in G1 and G2) or apoptosis. Both p15
INK4b
and p16INK4a are able to induce cell-cycle arrest in G1 by
inhibiting the cyclin-dependent kinases CDK4 and
CDK6 to inactivate the retinoblastoma (RB1) family of
tumor suppressor proteins [9, 10].
In the present study, we report microsatellite alterations
(LOH) on chromosomes 9p using different markers along
with comprehensive immunohistochemical analysis and
correlate this with the long-term outcomes of patients
with ccRCC after surgical excision with curative intent.
Methods
Study cohort
The Tayside Urological Cancer Network (TUCAN)
databases were searched for consecutive patients who
underwent radical nephrectomy for clinically localized
Renal Cell Carcinoma (RCC) between Jan. 2001 and
Dec. 2005. This is similar cohort described previously
[5]. Patients with cytoreductive nephrectomy were
excluded from this study. The period was chosen so that
a minimum of 9 years follow-up for each patient is ob-
tainable. Ethics approval (Ref. 12/ES/0083) was obtained
from the Tayside Research and Ethics committee. A
single pathologist (SF) with special interest in renal
cancer reviewed all the samples using pathology number
identifier for each patient. Patients were followed up
using standard department similar to already described
in our previous publications [11, 12].
DNA extraction from paraffın-embedded tissues
DNA was isolated from the paraffin-embedded tissues
according to the Qiagen EZ1 BioRobot method [13].
This extraction protocol relies on the use of magnetic
particles which bind to the DNA and are subsequently
removed from the surrounding tissue by a separate mag-
netic source. Briefly the curls of tissues were extracted
with 1 ml of xylene to remove the paraffin and then
treated twice with 1 ml of 95 % ethanol. After air-drying,
tissue pellets were digested in 180 μl of tissue lysis buffer
containing 0.1 M Tris–HCl (pH 8.0), 1 mM EDTA,
0.5 % Tween 20 and 20 μl proteinase K at 56 °C over-
night. Digested mixtures were heated at 90 °C for 5 min
to inactivate proteinase K. Supernatants were aliquoted
to fresh Eppendorf tubes, then diluted to a final volume
of approximately 400 μl by addition of 200 μl of 10 mM
Tris–HCl (pH 8), 1 mM EDTA buffer and stored at
−20 °C until use.
PCR-LOH analysis
DNA was amplified using PCR and analysed for LOH on
chromosome 9 using 6 different polymorphic DNA
markers. Briefly 50 to 100 ng of DNA (1 μl) were ampli-
fied by PCR in 25 μl of solution containing 2.5 mM each
of dATP, dGTP, dCTP, and dTTP; 1 μCi [1-32P] dCTP;
5 μM forward and reverse primers; 0.1 μl (0.5U) HotStar
Taq Start antibody (Clontech, Palo Alto, CA); and 1 unit
of Taq polymerase (Perkin-Elmer, Foster City, CA) in 10
PCR buffer [10 mM Tris–HCl, 50 mM KCl and 1.5 mM
MgCl2 at pH 8.3 (Perkin-Elmer)]. PCR was started at
95 °C for 15 min, followed by 35 cycles of denaturing
(95 °C for 40 s), annealing (55° for 40 s), and chain
extension (72 °C for 40 s), followed by 7 min at 8 °C
and 1 min at 4 °C. The primer sequence and annealing
temperature for each pair of primers are listed in Table 1.
The PCR product (0.5 μl) was denatured in deionised
fomamide and the fluorescent markers were analysed by
capillary electrophoresis. Determination of loss of hetero-
zygosity (LOH) was carried out using GeneMarker® soft-
ware V2.4.0 (SoftGenetic®, State College, PA 16803, USA).
El-Mokadem et al. BMC Cancer 2016, 15: Page 2 of 10
http://www.biomedcentral.com/1471-2407/15/1/
For informative cases, allelic loss (or possible allelic imbal-
ance) was scored if one allele was significantly decreased
in tumor DNA (40 %) compared with the same allele in
normal control DNA.
Immunohistochemistry
Immunostaining was used to identify p14, p15, p16, CAIX,
and ADFP protein expressions in renal cancer and normal
samples. Antigen retrieval and de-paraffinisation was
performed using DAKO EnVision™ FLEX Target Retrieval
solution (high pH) buffer in a DAKO PT Link. Immuno-
staining using DAKO EnVision™ FLEX system on a
DAKO Autostainer Link48 was carried out according to
manufacturer’s protocol. Sections were incubated with
primary antibody for 30 mins. DAKO substrate working
solution was used as a chromogenic agent for 2 × 5mins
and sections were counterstained in EnVision™ FLEX
hematoxylin. Sections known to stain positively were in-
cluded in each batch and negative controls were prepared
by replacing the primary antibody with DAKO antibody
diluent. The primary investigator, blinded to clinical out-
come, FISH, and microsatellites results, scored TMA
slides for p14, p15, and p16 antibodies using a Nikon
Eclipse E600 microscope. The scoring consisted of 2 dif-
ferent techniques based on the intensity of cytoplasmic
immune-staining on a 4-point scale (Table 2) and the
percentage of nuclei with immune-staining in each core
based on 3-point scale (Table 2). Both systems were
applied for p14, p15, and p16 antibodies. In contrast, only
the 4-point scale for cytoplasmic immune-staining was
employed for scoring ADFP and CAIX antibodies. The
scoring process was supervised and confirmed by a
specialist consultant renal pathologist.
Statistical analysis
The number of cores and nuclei scored by each observer
was compared. The level of interobserver agreement upon
validity of scoring and deletion status per represented
block of tumour was assessed using Kappa statistical
analysis. The clinicopathological data was compared based
on LOH status. Proportions between categorical variables
were compared using Fisher exact and Pearson chi-square
tests, as appropriate. The survival time was summarised
using median and interquartile ranges (IQR). Other con-
tinuous variables were summarised as mean and standard
deviation (SD), and compared using Student-t tests or
Mann–Whitney U test as appropriate.
The Kaplan-Meier method was used to estimate RFS
and DSS based on LOH status and other variables. The
log-rank test was used to compare the survival differ-
ences between the groups.
A Cox-proportional hazard model was used to assess
the correlation between prognostic variables and recur-
rence, and RCC-specific mortality. Multivariate analysis
was performed for DSS and RFS after excluding the in-
significant variables on univariate analysis. For DSS, 2
models were generated. A backward selection manner
with the likelihood ratio criterion (for entry and removal:
p ≤ 0.05 and p > 0.1 respectively) and rank of elimination
was used to identify the most significant variables to be
entered in a final model for RFS and 2 final prognostic
models for DSS. Statistical analysis was performed using
IBM® SPSS® – version 21, with all tests being two-tailed
and p < 0.05 considered statistically significant.
Results
There were 77 ccRCC tumour/normal interpretable pairs
for LOH analysis. Figure 1a and b show different loci on
chromosome 9 of renal cancer tissues and summarizes
microsatellite analysis profile. LOH was identified with at
least for 1 marker in 20 of 77 (26 %) cases. Most allelic
deletions were detected, telomeric to CDKN2A region at
D9S916, with 11 out of 52 informative tumours (21 %)
displaying LOH. For the 2 microsatellites within CDKN2A
Table 1 Shows the sequences of microsatellite markers used in
the study
Primers Sequence
D9S916 Forward 5’- gatgtccagttgtcccttcataa -3’
Reverse 5’- atagactgccaaatttttggacc -3’
D9S974 Forward 5’- cctggtctggatcataaaatgaa -3’
Reverse 5’- tgtggaaattttctgtctggttc -3’
D9S942 Forward 5’- aagcaagattccaaacagtaaaca -3’
Reverse 5’- ttcgtttcacttttgagttttcc -3’
D9S1814 Forward 5’- tgtcagtggtatttacctttttgg -3’
Reverse 5’- cagaaggtcagtaggttcacagg -3’
D9S171 Forward 5’- agctaagtgaacctcatctctg -3’
Reverse 5’- tgattgttaataaagtagcccc -3’
Table 2 Shows methodology of scoring of immunohistochemistry
for various proteins expressed in normal and renal cancer
Cytoplasm staining Score Interpretation
X Core loss
N Normal renal tissue
0 No uptake of stain
1 Diffusely or focally weak uptake of the stain
2 Diffusely or focally moderate uptake or
focally intense
3 Diffusely intense
Nuclear staining Score Percentage Nuclei Stained %
1 0–10 %
2 >10 but <50 %
3 ≥50 %
Non-integral values were rounded up to close integral figure
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coding region, ten out of 58 informative cases (17 %) and
9 out of 62 informative cases (14.5 %) displayed LOH at
D9S974 and D9S942 respectively. In contrast, centromeric
to CDKN2A coding region, D9S1814 showed LOH in 3
out of 38 cases (7.8 %), which was the lowest rate of LOH
as well as informative cases out of the 5 primers. D9S171
(9p13) showed allelic deletion in 11 out of 57 informative
tumours (19 %). A summary of the renal cell carcinoma
cases with grade, stage, and LOH on chromosome 9 is
given in Table 3. Additional file 1: Figure S1 shows the
representative LOH at chromosome 9p in human renal
cancer. There were deletions on loci D9S162, D9S1748,
D9S171, D9S270, and D9S153 of chromosome 9p. Figure 2
is an example showing pattern of protein expression on
immunohistochemistry profile seen. The level of expres-
sion (none to strong) of different proteins was compared
between ccRCC and control normal renal tissues. The
levels of expression of p14, p15, and p16 in ccRCC were
statistically significantly lower compared to their levels of
expression in normal renal tissue (Table 4). On the other
hand, there was no difference in the degree of expression
between ADFP and CAIX expression between ccRCC and
normal renal tissue.
Clinicopathological significance of LOH and proteins
expression
Cases displaying LOH at least in one marker on 9p21
were highly significantly associated with higher risk of
RCC-specific death compared to cases with no allelic
deletion (Fig. 3a-c). This was mostly observed with LOH
in the 3 markers within this region with the highest
number of informative cases: D9S916, D9S974, and
D9S942. These were statistically significant on multivari-
ate analysis (Table 5).
Also, LOH at D9S171 (9p13) showed a trend towards
worse prognosis, but did not reach statistical signifi-
cance. The markers showed significant association with
RCC recurrence (Log-rank: p = 0.014; Fig. 3d).
Out of the 65 informative cases, 59 had valid im-
munohistochemistry scoring. The level of expression
of all protein markers correlated with the LOH at
least in one of the microsatellites at chromosome 9p.
The level of p16 cytoplasmic expression significantly
correlated with LOH involving at least one of the
microsatellites at 9p21 and was less in LOH cases
compared with normal 9p status (Mann–Whitney U:
p = 0.011).
Fig. 1 a and b Show outcome of microsatellite status at chromosome 9p using 5 different markers. Clear circle represents normal, black circle
represents loss of heterozygosity (LOH), crossed circle represents non-informative and F represents failed
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A significant trend was seen between pathological
stage and p14 cytoplasmic expression (p = 0.062; r =
−0.169), p14 nuclear immunohistochemical staining
(p = 0.07; r = −0.187). Similarly, positive correlation
was observed with p15 nuclear expression (p = 0.09;
r = 0.178). Lower ADFP expression was associated
with higher Furhman grade (p = 0.021; r = −0.218;
Fig. 4) tumours and the mean ADFP expression in
9p-deleted tumours was significantly lower compared
to tumours with normal 9p status (1.87 and 2.25
respectively; p = 0.015). It was noted that the high
levels of ADFP expression were associated with high
levels of CAIX (p = 0.008; r = 0.293; Fig. 5) and p16
cytopalsmic expression (p = 0.004; r = 0.318).
Discussion
This study investigated the association between loss of
heterozygosity (LOH) in the region of chromosome
9p21, immunohistochemical expression of a number of
proteins associated with the region, staging (lower vs.
higher) of renal cancers and long-term outcome follow-
ing resection of clinically localized renal cancer. Micro-
satellite analysis using five biomarkers investigated this
relationship. The main allelic deletion was detected at
loci telomeric to CDKN2A region at D9S916, with 11
out of 52 informative cases (21 %) displaying LOH.
The frequency of LOH was directly linked to the
stage (p = 0.005) and metastases (p = 0.006) of the tu-
mours, indicating a higher frequency of LOH is associated
Table 3 Correlation between loss of heterozygosity of chromosome 9p and various tumour characteristics in clinically localized
renal cell carcinoma
D9S916 D9S974 D9S942 D9S1814 D9S171
Variables Normal LOH p= Normal LOH p= Normal LOH p= Normal LOH p= Normal LOH p=
Tumour size Mean 5.3 4.6 0.93 4.8 6.4 0.76 4.8 6.4 0.17 4.8 6.4 0.77 5.1 5.3 0.66
SD (±3.2) (±2.1) (±2.9) (±3.4) (±2.9) (±3.4) (±2.9) (±3.4) (±3.2) (±2)
T stage pT1 20 4 0.005 28 2 0.004 29 2 0.003 19 0 0.028 22 5 0.42
pT2 12 0 7 1 11 0 8 0 12 0
pT3 9 5 13 5 13 6 7 3 12 5
pT4 0 2 0 2 0 1 1 0 0 1
pT1/2 32 4 0.02 35 3 0.02 40 2 0.004 27 0 0.02 34 5 0.084
pT3/4 9 7 13 7 13 7 8 3 12 6
Metastasis N0M0 38 8 0.1 46 6 0.006 50 5 0.006 33 2 0.224 42 8 0.12
N +M+ 3 3 2 4 3 4 2 1 4 3
Fuhrman Grade G1/G2 16 4 1 18 2 0.47 20 2 0.47 14 1 1 18 3 0.73
G3/G4 25 7 30 8 33 7 21 2 28 8
Tumour necrosis Present 10 3 1 14 3 1 16 1 0.42 10 0 0.55 14 3 1
Absent 29 7 33 6 35 7 23 3 30 7
Sarcomatoid change Present 1 3 0.02 2 2 0.12 4 1 0.53 4 1 0.37 3 2 0.23
Absent 38 7 45 7 47 7 29 2 41 8
Microvascular invasion Present 10 2 1 11 3 0.68 13 3 0.67 9 1 1 12 3 1
Absent 28 8 36 6 38 5 23 2 31 7
Renal Vein invasion Present 6 2 1 8 2 0.67 8 2 0.62 3 1 0.32 7 2 1
Absent 31 8 37 7 41 6 28 2 34 8
Pelvicalyceal invasion Present 4 0 0.56 6 1 1 6 1 1 2 1 0.25 7 0 0.32
Absent 33 10 39 8 43 7 29 2 34 10
Renal sinus invasion Present 3 4 0.03 5 4 0.03 5 4 0.016 3 2 0.068 5 4 0.06
Absent 34 6 40 5 44 4 23 1 36 6
SSIGN score 0–2 17 5 0.16 21 3 0.26 22 2 0.29 16 1 0.011 17 4 0.43
S – Stage 03–Apr 4 0 7 0 6 1 4 0 4 0
SI – Size 05–Jun 11 1 9 2 11 2 3 1 10 3
G – Grade 07–Sep 4 2 6 2 8 1 8 0 8 1
N - Necrosis ≥10 1 2 2 2 2 2 0 1 2 2
Numbers in columns under normal and LOH represent number of patients
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with a more aggressive renal cell cancer. There was a
significantly higher risk of cancer related death in patients
showing LOH in at least one marker on 9p21 in compari-
son to those patients with no allelic deletion. Loss of het-
erozygosity at chromosome 9p was associated with
p14ARF, p15INK4b, p16INK4a, adipose related differentiation
protein (ADFP) and carbonic anhydrase IX expression.
Loss of expression of p14ARF, p15INK4b, p16INK4a, and
ADFP was significantly associated with aggressive tu-
mours and poor prognosis. In addition to these key find-
ings, the observations from this study contribute not only
to estimation of the molecular pathophysiology renal can-
cer, but also to the improvement of clinical management
of patients with renal cancer through the provision of bet-
ter prognostic prediction.
LOH is an allelic imbalance that is used to detect
tumour suppressor genes and genomic regions which
may correlate with tumour grade, stage, and progression.
Microsatellites have proved to be important genetic
markers in analysing LOH, however, studying LOH
using these markers has been limited due to the tedious
nature of the genotyping procedure. There have been a
number of studies investigating more effective ways of
analysing LOH. Studies have shown that LOH and copy
Fig. 2 Shows an example of variation in immunohistochemical staining pattern (negative to strong) seen in normal and cancer tissues for various
proteins with common origin from chromosome 9p. Overall, normal tissue strong staining pattern compared to corresponding cancerous tissue.
Methodology described in Table 2 was used to quantify the staining pattern of immunohistochemical expression
Table 4 Percentage and expression level of nuclear










P14 <10 % 70 1 <0.001
11–50 % 8 6
>50 % 4 13
Mean expression (SD) 1.336 (0.56) 2.714 (0.42)
P15 <10 % 76 20 <0.03
11–50 % 4 0
>50 % 0 0
Mean expression (SD) 0.970 (0.58) 1.631 (0.36)
P16 <10 % 72 6 <0.001
11–50 % 9 10
>50 % 1 4
Mean expression (SD) 1.441 (0.62) 1.809 (0.31)
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number aberrations (CNA) analysis by high-density sin-
gle – nucleotide polymorphism (SNPs) arrays can be
used effectively in identifying possible changes in genes
[14]. In one study, polymerase chain reactions (PCR)
were performed on a large number of SNPs for LOH
and the amplified products of PCR were hybridised to a
high-density oligonucleotide array. It was found that the
relationship of LOH in cases directly corresponds with
findings in genomic hybridization [15]. In a similar
study, with larger numbers of SNP markers were shown
to rapidly detect allelic imbalances; the results were
validated by comparing them with analysis of the same
tumours using the microsatellite allelotype method. The
comparison successfully demonstrated consistent results
between the two methods in identifying genomic imbal-
ances [16].
Affymetrix 10 K SNP genome-wide mapping arrays
have been studied and the results remain consistent with
the existing literature, proving the effectiveness of SNP
arrays analysis in detecting LOH and other chromo-
somal alterations. Toma et al. [17] confirmed that SNP
array analysis is an important method of detecting novel
microdeletions and may be involved in the progression
of cc-RCC, as well as confirming larger chromosomal
imbalances. The clinical application of LOH analysis
have been investigated including its value in predicting
prognosis and patient outcomes. Allelic loss using poly-
morphic microsatellites have been used to determine the
progression of papillary renal cell carcinoma [18]. It is
suggestive that LOH at chromosomes 8p12-21.1, 9p21,
and 14q24.2-qter regions directly corresponds to higher
tumour grade and pathological progression.
The importance of 9p status in cancer progression and
patient outcomes has been of a matter great research
interest for many years. However, the application of this
genetic information has yet to progress to the clinical
setting, and a few would question application of this in-
formation in healthcare. A recent systematic review [19]
carried out to assess the quality of studies reporting the
significance of 9p chromosomal abnormalities in RCC
and to assess whether it could be used as a tool to
predict oncological outcomes in RCC. Looking at 11
studies, including a total of 1431 patients, it was found
that more work including standardization of techniques
were needed to validate the clinical role of 9p status.
Throughout the review, the studies lacked consistent
Fig. 3 Number of figures in this group show disease specific survival and recurrence free survival in patients with loss of heterozygosity for various
markers. a Shows poor survival in patients with loss of heterozygosity for D9S916 b Shows poor survival in patients with loss of heterozygosity for
D9S974; c Shows poor survival for patients with loss of heterozygosity for more than 1 loci on 9p21 region. d shows poor recurrence free survival of
renal cancer patients following surgery with loss of heterozygosity on CDKN2A region
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interpretation of results and investigation into clinical
application. The review called for more research into the
9p status predicting clinical outcomes, with a greater
focus on the clinical application and a higher quality of
research methodology and reporting.
Cancer staging and grading have long been the accepted
methods of evaluating patient outcomes. Prognosis of
renal cell cancer is conventionally predicted using staging
and grading, relying on variables such as tumour morph-
ology, tumour size, lymph node or distant metastatic
spread and vascular invasion. However, there are limita-
tions in using these traditional classifications as they are
ineffective in accurately assessing which post-surgical
patients are high risk of recurrence and most certainly fail
to identify patients who would benefit from more closer
follow up and adjuvant therapies. Using histopathological
Fig. 4 a Correlation between ADFP expression and histopathological grade of cancer (p = 0.021). b Also, see a good correlation between ADFP
expression status and 9p deletion (p = 0.015)
Table 5 Shows summary of univariate and multivariate analysis. Note highlighted significant p-Values
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variables, the patient sub groups are too broad and there
is variation within the individual sub groups which make
predictive values of these measure inaccurate. It has been
investigated by El-Mokadem et al. [5] as to whether inter-
phase fluorescent in situ hybridisation (I-FISH) scoring
can be used as an alternative for predicting disease-free
survival and recurrence rates. Tissue microarrays were
constructed from paraffin-embedded renal cell tumour
tissue and I-FISH was used to determine 9p status. Pa-
tients were followed up for a median of 95 months and it
was found that 9p deletion was an indicator of higher risk
recurrence (P = 0.008) and RCC-related death (P = 0.001).
It was also found that using 9p status with the SSIGN
(stage, size, grade, and necrosis) score significantly in-
creased the predictive accuracy from 87.7 to 93.1 %.
It has been found that 9p chromosomal deletions are
linked with more aggressive cancers that have a higher
risk of metastatic spread following nephrectomy for lo-
calized RCC [20]. Deletion in 9p can be commonly seen
in a number of epithelial tumours. It is often present in
larger tumours with higher grade and stage, however, it
can also be found in less aggressive, smaller tumours, and
9p status still successfully predicts disease recurrence in
these cases. To investigate LOH on 9p, 5 microsatellite
markers of this region were identified and patients were
followed up, looking at the association of 9p chromosome
deletion with prognosis of patients after potentially cura-
tive nephrectomy. In a multivariate analysis, it was found
that LOH at 9p21 chromosome achieved a statistical sig-
nificance and accurately predicted survival or risk of RCC
recurrence in patients following surgery.
Cyclin dependent kinases locus on chromosome 9p21
encodes for three cell cycle inhibitory proteins: p15INK4b
encoded by CDKN2b, p16INK4a encoded by CDKN2a
and p14ARF encoded by an alternative reading frame of
CDKN2a [21]. There is often co-deletion of these loci in
most of cancers in human. The present study is first
comprehensive study of these proteins and ADFP in hu-
man renal cancer tissues. Experimental data suggests
CDKN2AB −/− knockout mice develop aggressive and
multiple tumours - suggesting tumour suppresser role of
these proteins. Our observation and previously published
study [22] confirms the expression of p16 protein is absent
or low in renal cell cancer samples, suggesting that loss of
the p16 gene may be key event involved in renal cell can-
cer. Cyclin-dependent kinase (CDK) inhibitor p16INK4a
protein is a member of the INK4 family of cell cycle regu-
latory proteins and specifically inhibits the formation of
cyclin D1-CDK4/6 complexes [23, 24]. The later controls
the activity of retinoblastoma tumor-suppressor protein
pRb by phosphorylation. Phosphorylated pRb then disas-
sociates from the E2F transcription factor family of pro-
teins. The E2F transcription factors are then able to
reprogram the cell to enter the S phase [25]. Dephosphor-
ylated retinoblastoma protein arrests proliferating cells in
G1 phase of the cell cylce. From the published literature,
it is reasonable to assume that the cellular response to
hypoxia, a common feature in renal cancers involves re-
versible cell cycle arrest characterized by dephosphory-
lated Rb, loss of CDK activity, and decreased cyclin
synthesis. We also study expression of ADFP, a protein
encoded by 9p21 and reported by us previously. The ex-
pression of protein correlated with 9p deletion and grade
of cancer. Also, its expression correlated with two other
known proteins such as CAIX and p16. In contrast to pre-
vious studies [26, 27], CAIX was not found to be associ-
ated with aggressive tumours or long-term prognosis.
Conclusions
In conclusions, the study has confirmed previous findings
that p21 region harbours one of the tumour suppressor
genes and the loss of heterozygosity in this region is
associated with aggressive tumours and predicted poor
clinical outcomes on long-term. The loss of expression of
cell-cycle related proteins and ADFP is associated with
aggressive cancers.
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Fig. 5 Correlation between ADFP expression and other two proteins (CAIX and P16) known to be in the region of CKDNA2 on chromosome 9p
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